United States Patent 12,564,587 (US 12,564,587): Claim Scope, Enforceable Boundaries, and US Patent Landscape for Bupropion–Dextromethorphan–Alcohol Minimization in Alzheimer’s Agitation
US 12,564,587 is directed to a specific seizure-avoidance regimen in Alzheimer’s disease agitation. The core independent claim requires (1) selecting an Alzheimer’s agitation patient who is consuming alcohol, (2) administering a twice-daily oral dosage form to avoid seizures, and (3) advising alcohol minimization without abrupt discontinuation, with the dosing tied to sex-specific daily alcohol serving limits. The dosage form is tightly constrained to bupropion hydrochloride (105 mg), dextromethorphan hydrobromide (45 mg), plus a polymer, with extensive dependent-claim narrowing to specific excipients and release profiles (immediate-release dextromethorphan; extended-release bupropion), and tablet/bilayer embodiments.
Because the request is to analyze the “scope and claims and patent landscape” for US 12,564,587, a complete and accurate landscape requires the patent’s full text (specification and claims), bibliographic data (filing/priority), prosecution history, and the asserted family members and related patents in the same claim set. That information is not present in the prompt beyond the quoted claims. Without the patent document itself, an authoritative landscape that is fit for licensing, litigation, or regulatory strategy cannot be produced without risking factual errors.
H1: US 12,564,587 Claim Scope: Bupropion–Dextromethorphan Dosage, Alcohol Minimization Counseling, and Seizure Avoidance in Alzheimer’s Agitation
What does independent claim 1 require in combination?
Independent claim 1 is a three-part method claim plus a structural dosage-form limitation and sex-specific counseling limits. It is written to be practiced in the real-world with a prescribing clinician and patient behavior.
A. Patient selection element
- “Selecting a human patient with agitation associated with Alzheimer's disease who is consuming alcohol.”
B. Administration element
- “Administering a dosage form twice a day … to avoid seizures.”
C. Counseling element
- “Advising the human patient to minimize, but not abruptly discontinue, alcohol consumption.”
D. Dosage-form composition element (hard constraints)
- Bupropion: “105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form … or the free base”
- Dextromethorphan: “45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form … or the free base”
- Plus “a polymer”
E. Sex-specific alcohol serving thresholds after advice
- Adult male: “two servings or less of alcohol per day”
- Adult female: “one serving or less of alcohol per day”
This is not just a formulation claim. The claim ties composition, dosing frequency, clinical counseling, and patient alcohol behavior into a single method.
How claim 1’s “avoid seizures” limitation narrows enforceable practice
“to avoid seizures” is a functional outcome tied to the regimen. In enforcement, defendants will typically argue non-infringement by separating:
- seizure avoidance from the counseling,
- seizure avoidance from the twice-daily dosage form,
- or the patient not meeting the “consuming alcohol” selection criterion.
But because the claim expressly requires each element, non-infringement arguments typically focus on missing elements rather than disputing “avoid seizures” causation.
What changes in claim 21
Claim 21 repeats the same selection, administration, and counseling structure but hard-codes the dosage form to:
- “105 mg of bupropion hydrochloride, 45 mg of dextromethorphan hydrobromide, and a polymer”
The difference from claim 1 is that claim 21 removes the “molar equivalent” language for alternate bupropion/dextromethorphan salt forms or free base. That makes claim 21 narrower, more literal, and easier to compare to a product label if there is an exact salt form match.
H2: What patents protect seizure avoidance for Alzheimer’s agitation patients who consume alcohol using bupropion and dextromethorphan?
A complete US patent-protection map depends on:
- the patent’s citation list and family,
- related continuations/divisionals,
- and co-pending method and formulation claims across the same assignee.
With only the asserted claims text provided, the US patent landscape cannot be built accurately. Any attempt to list other patents, assignees, or expiration dates would require access to the US 12,564,587 full record and its bibliographic/prosecution data.
What can be concluded from claim text alone
- The protection is framed as a method-of-treatment plus dosing regimen, not a general seizure-prevention strategy. It is tied to Alzheimer’s agitation and the specific bupropion/dextromethorphan dosage and alcohol-minimization counseling with sex-specific thresholds.
- Competitors designing around will look for carve-outs:
- different drug dose strength,
- different salts without “molar equivalent” mapping,
- different counseling language and/or different thresholds,
- different dosing frequency (only claim 1 and 21 specify twice daily; other dependent terms may exist in the full document),
- different patient selection criteria (no “consuming alcohol” step, or alcohol status defined differently).
H2: How many claims are directed to specific formulation excipients and release profiles under US 12,564,587?
Based on the dependent claims provided:
Immediate-release (IR) and extended-release (XR) split
- Claim 2: “dosage form provides immediate release of the dextromethorphan.”
- Claim 3: “dosage form provides extended release of the bupropion.”
This indicates a combined release system: IR for dextromethorphan and XR for bupropion.
Excipients explicitly covered
Claims 4–13 name specific excipients:
- Claim 4: colloidal silicon dioxide
- Claim 5: crospovidone
- Claim 6: glyceryl monocaprylocaprate
- Claim 7: L-cysteine hydrochloride monohydrate
- Claim 8: magnesium stearate
- Claim 9: microcrystalline cellulose
- Claim 10: polyvinyl alcohol
- Claim 11: sodium lauryl sulfate
- Claim 12: stearic acid
- Claim 13: titanium dioxide
Polymer constraint for the dosage form
- Claim 14: polymer is “carbomer homopolymer”
Dependent claim with broader excipient list
- Claim 15: further comprises a longer list of named excipients and/or combinations (includes red/yellow iron oxides and talc as well, based on the provided text).
Dosage form type
- Claim 16: dosage form is a tablet
- Claim 17: tablet is a bilayer tablet
Duration limits
- Claim 18: at least 4 weeks
- Claims 19–20: 1–3 months; and 3–6 months
This creates temporal enforceability: practice outside the recited durations may avoid dependent-claim scope, but still potentially fall within the independent claim if the independent claim is not constrained by duration (it is not, based on the text provided).
H2: When does US 12,564,587 lose exclusivity for generics or Paragraph IV challenges in the US?
No loss-of-exclusivity dates can be derived from the claim text alone. US patent exclusivity and FDA regulatory exclusivity are determined by:
- the patent’s priority and filing dates (for the 20-year term),
- any patent term adjustment (PTA) and patent term extension (PTE),
- whether it is listed in the Orange Book,
- and whether it is a method-of-use or method-of-treatment patent that can be triggered by a Paragraph IV filing for a specific NDA/BLA.
With the full patent bibliographic record and Orange Book listing status absent from the prompt, an exclusivity timeline would be speculative.
H2: What Orange Book status does US 12,564,587 have, and is it listed for a specific NDA?
Orange Book status cannot be determined from the provided claim text. It requires:
- drug product identity,
- NDA/BLA number,
- dosage form and strength mapping to the listed patent,
- and the patent’s “type” (drug substance, drug product, method of use).
This cannot be produced accurately without the patent record and Orange Book listing.
H2: What generic entry risks exist for a bupropion-dextromethorphan product targeting Alzheimer’s agitation with alcohol counseling?
From claim construction alone, the generic-entry risk is elevated if a generic seeks to market a product that is substituted into a twice-daily regimen and is used with counseling consistent with claim 1, including sex-specific alcohol serving thresholds.
Likely risk drivers for a generic manufacturer
- The dosage strength matching: 105 mg bupropion HCl and 45 mg dextromethorphan hydrobromide.
- The release profile: IR dextromethorphan and XR bupropion (if the labeled regimen or product design matches).
- The polymer: at least a polymer component (claim 1); and potentially specifically carbomer homopolymer (dependent claim 14).
- The tablet/bilayer structure (dependent claims 16–17).
- The specific counseling: “minimize, but not abruptly discontinue,” plus male/female “servings per day” thresholds.
Likely design-around vectors
A product or clinician practice could attempt to avoid the claim by changing at least one required element:
- dose strength not meeting literal “105 mg/45 mg” mapping (and avoiding reliable “molar equivalent” equivalence),
- not using twice-daily dosing (if the independent claim is strictly applied),
- not advising “minimize but not abruptly discontinue,” or using different thresholds,
- not selecting a patient “who is consuming alcohol” as defined in the claim practice.
However, effectiveness of counseling-based design-arounds depends on how the patent is interpreted and on the practical evidence of label and practice patterns.
H2: How do the dependent claims affect infringement analysis for formulation and excipient variants?
Dependent claims 4–15 and 16–20 narrow embodiments. In infringement analysis:
- If an accused regimen includes all elements of independent claim 1, dependent-claim differences may matter for claim-by-claim matching, remedies, and settlement leverage.
- If an accused product or method deviates from independent claim elements (dosage composition, twice-daily administration, counseling with sex thresholds), the dependent variations may be irrelevant to direct infringement of the broader method.
Excipients: more likely to matter for manufacturing design and label comparison
Because dependent claims list many excipients, an accused product that differs in excipient selection could potentially avoid those dependent claims while still matching independent claim 1’s polymer and active ingredients.
Release profile: key for product design
Claims 2–3 create a formulation-level constraint tied to release. If an accused product does not provide IR dextromethorphan and XR bupropion, it may avoid those dependent claims, though again not necessarily independent claim 1.
H2: What does the claim language imply about the drug delivery system and polymer use?
The claim requires a dosage form “and a polymer.” That is broad enough to cover multiple polymer types for independent claim 1. Dependent claim 14 narrows that polymer to carbomer homopolymer.
A bilayer tablet embodiment (claim 17) is consistent with the IR/XR split. If both release characteristics are needed for the product’s clinical performance, the bilayer concept is likely tied to claim scope leverage.
H2: Are seizures tied to alcohol use discontinuation risks, and how does that shape enforceable counseling scope?
The counseling is explicit:
- minimize alcohol
- do not abruptly discontinue
and it includes measurable limits by sex:
- male: ≤2 servings/day
- female: ≤1 serving/day
This makes the counseling a definitional element for claim scope. A dispute will typically focus on:
- whether the patient was “consuming alcohol” at selection,
- whether counseling included “minimize” without abrupt discontinuation,
- and whether the serving thresholds were communicated and followed.
H2: Which companies are challenging or defending US 12,564,587 through Paragraph IV or IPR, and what are the case outcomes?
No litigation or IPR information is present in the prompt. A reliable landscape requires docket data (RECAP/USPTO Patent Trial and Appeal Board filings), court filings, and settlement terms tied to US 12,564,587. Without those inputs, the analysis cannot be completed without risking inaccuracies.
H2: How strong is the patent estate for bupropion-dextromethorphan Alzheimer’s agitation seizure avoidance methods?
Strength cannot be assessed without:
- the full specification,
- prosecution amendments and claim construction record,
- and whether there are overlapping families with independent claims that capture the same commercial product design from multiple angles (formulation, release, regimen, counseling).
The claim text provided supports a specific and enforceable combination. But comprehensive strength analysis for an estate is not possible without the rest of the patent file and related family members.
Key Takeaways
- US 12,564,587 is a method-of-treatment patent that requires a combined regimen: twice-daily administration to Alzheimer’s agitation patients who are consuming alcohol, paired with counseling to minimize alcohol but not abruptly discontinue, and sex-specific alcohol serving thresholds.
- The dosage form is constrained in independent claim 1 to bupropion HCl (105 mg) and dextromethorphan HBr (45 mg), plus a polymer; dependent claims narrow salt selection by omission in claim 21 and narrow polymer identity to carbomer homopolymer.
- Dependent claims define additional formulation constraints: IR dextromethorphan, XR bupropion, tablet/bilayer, and multiple specific excipients.
- A full US landscape (expiration, Orange Book status, generic entry and Paragraph IV posture, litigation, and related families) cannot be produced from the provided claim text alone.
FAQs
- Can a generic avoid infringement if it changes counseling language about alcohol discontinuation?
- If a product matches the active ingredient amounts but uses different salts, does independent claim 1 still cover it?
- Does the bilayer tablet requirement apply only to dependent claim 17 or also to independent claim 1?
- How do IR/XR release limitations affect design-around for sustained-release bupropion and immediate-release dextromethorphan?
- If treatment duration is outside 1–6 months, does it still infringe the independent claim?
References
- United States Patent Application/Patent record for US 12,564,587 (not provided in the prompt).
